Story
Hyatt Shares Fall 9% After Cutting Key Net Rooms Growth Forecast

Summary
Hyatt Hotels stock dropped sharply after the company lowered its full-year outlook for net rooms growth, a critical investor metric, and cited pressures from conflict in the Middle East and a slow recovery in Mexico.
Hyatt Hotels (NYSE: H) shares plunged as much as 9% on Thursday after the company lowered its full-year forecast for net rooms growth and highlighted the impact of geopolitical and regional pressures on its business.
Growth Outlook Disappoints Investors
The Chicago-based hotel operator announced it now expects full-year net rooms growth of approximately 6%, trimming the upper end of its previous forecast of 6% to 7%. According to a Reuters report, CEO Mark Hoplamazian stated that Hyatt was taking a "measured view on the timing of openings" for the rest of the year.
Analysts noted that this metric is a primary focus for Wall Street. Jefferies analyst David Katz said that net unit growth is a "more prominent driver of valuation" than revenue per available room (RevPAR) and that the revision would likely cause an "outsized reaction" in the stock. Analysts at J.P. Morgan also attributed the share decline to the reduced growth forecast.
AdGeopolitical and Regional Headwinds
Hyatt also detailed specific challenges that affected its second-quarter results. The company said that ongoing geopolitical tensions in the Middle East shaved approximately 110 basis points from its room revenue growth during the period.
Furthermore, Hyatt signaled a slower-than-expected recovery in Mexico following regional unrest earlier in the year. While booking trends have improved sequentially, the company described the pace as "slower than previously anticipated." These headwinds emerged despite continued strength in Hyatt's luxury and upper-upscale brands, a positive trend also reported by rival Hilton (NYSE: HLT) amid resilient demand from affluent travelers.
Read next
More on Stocks
Iovance Biotherapeutics Lifts 2026 Revenue Outlook, Shares Jump
The biotechnology firm raised its full-year revenue guidance to between $410 million and $420 million, beating analyst estimates and citing strong demand for its cancer therapies.

JPMorgan Downgrades Monday.com to Neutral on Slowing Customer Growth
The investment bank lowered its rating on the work management software company, citing a decline in new recurring revenue and longer sales cycles among smaller businesses.

Insider Transactions: Meta, CrowdStrike CEOs Sell Stock; Executives Buy into REITs and Biotechs
Recent SEC filings show multi-million dollar stock sales by executives at Meta and CrowdStrike, mostly under pre-set plans, while leaders at Angel Oak Mortgage REIT and Inhibrx Biosciences made significant open-market purchases.

Plug Power Shares Rise on 280 MW Electrolyzer Deal for Danish Green Fuel Project
Plug Power has secured a major agreement to supply 280 MW of electrolyzers to Arcadia eFuels for a sustainable aviation fuel project in Denmark, causing its stock to climb in premarket trading.